AlphaVax Inc., a Durham, N.C.-based developer of vaccine products for infectious diseases, biodefense and cancer, has raised approximately $12.65 million in Series E funding. No additional information was disclosed. www.alphavax.com
AlphaVax Inc., a Durham, N.C.-based developer of vaccine products for infectious diseases, biodefense and cancer, has raised approximately $12.65 million in Series E funding. No additional information was disclosed. www.alphavax.com
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: